2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1373

Epigenetic Mechanisms Contribute to the Lack of LPS-Induced Tolerance in Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 1624

Epigenetic Profiling of CD14+ and CD16+ Monocyte Subtypes in Rheumatoid Arthritis. Alterations Related to Cardiovascular Disease and Endothelial Dysfunction
Abstract Number: 2466

Epigenetic Traits Correlate with Clinical Activity in Juvenile Idiopathic Arthritis
Abstract Number: 1262

Epigenome-Wide DNA Methylation Patterns Associated with Fatigue in Primary Sjögren’s Syndrome
Abstract Number: 3166

Epistatic Interaction of Functional Inflammasome Genetic Variants in Determining the Risk of Gout
Abstract Number: 1683

Epithelial Changes in Response to Tocilizumab Combined with Methotrexate in Rheumatoid Arthritis: Evaluated on Circulating Fragments of Type IV Collagen
Abstract Number: 1108

Epratuzumab, a Monoclonal Antibody Targeting CD22 on B Cells, Stimulates the Phosphorylation of Upstream Inhibitory Signals of the B Cell Receptor
Abstract Number: 3130

Epstein-Barr Virus Induces Activation of Infammatory Markers Via the TLR8 Transduction Pathway in Infected Scleroderma Monocytes
Abstract Number: 983

ERAP1 Deficiency Protects HLA-B27 Transgenic Rats from Arthritis
Abstract Number: 482

Erosions in the Foot at Baseline Are Predictive of Orthopedic Shoe Use after 10 Years of Treat to Target Therapy
Abstract Number: 2898

Erythrocytes, Acanthocytes, and Proteins in Urine Reflect Lupus Nephritis Histology
Abstract Number: 1807

Estimated Sodium and Potassium Intake Are Associated with Blood Pressure in Patients with Systemic Lupus Erythematosus
Abstract Number: 767

Estimating the Pre-Test Probability of Systemic Lupus Erythematosus By Utilizing Anti-Double Stranded DNA and Cell Bound Complement Activation Products Testing from Rheumatology Based Practices in the United States
Abstract Number: 1228

Estimating Under-Diagnosis of Rheumatoid Arthritis in Primary Care Data from the UK Clinical Practice Research Datalink
Abstract Number: 3010

Estrogens Inhibit the Profibrotic Effects of Transforming Growth Factor-Beta and Protect from the Development of Experimental Dermal Fibrosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].